The efficacy of hydroxyurea (HU) in myeloproliferative disorders is well documented. HU controls thrombocytosis both in polycythemia vera (PV) and in essential thrombocythemia (ET), while reducing the risk of thrombosis.1 Despite many anectodal reports, no evaluation of the prevalence and type of side effects of HU exists in large series of patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
myeloproliferative disorders
8
safety profile
4
profile hydroxyurea
4
hydroxyurea treatment
4
treatment patients
4
patients philadelphia-negative
4
philadelphia-negative chronic
4
chronic myeloproliferative
4
disorders efficacy
4
efficacy hydroxyurea
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!